Infinity Pharmaceuticals Inc. and Mundipharma International Corp. Ltd. have extended their R&D collaboration a second time, adding a $50 million commitment for 2013 to fund continued development of a dual phosphoinositide-3-kinase (PI3K) delta and gamma inhibitor for a range of indications.
The latest agreement, announced Nov. 29, adds to a 2008 collaboration that seemingly was modeled on the relationship between
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?